title: Complete response of sunitinib therapy for renal cell cancer recurrence in the native kidney after renal transplantation: a case report.
abstract: BACKGROUND
  No case report has yet shown that sunitinib therapy for the postoperative recurrence of renal cancer in a native kidney after renal transplantation can achieve complete response (CR).
  
  
  METHODS
  A tumor was detected in the right native kidney of a 35-year-old Japanese male 10 years after renal transplantation. A tumor thrombus that reached the atrium was detected, which suggested cT3cN0M0. Because of the risk of perioperative complications, preoperative therapy with sunitinib was selected and 8 courses were administered. The size of the primary tumor was reduced by 33%, while that of the tumor thrombus was decreased by 39.5%. Right nephrectomy and removal of the tumor thrombus were then performed. Contrast-enhanced computed tomography (CT) four months after surgery suggested local relapse. Sunitinib was administered for 9 months, which led to complete response (CR).
  
  
  CONCLUSIONS
  This study presented the case of sunitinib therapy for renal cancer in the native kidney after renal transplantation. The therapeutic efficacy and safety for such cases should be discussed.
authors.affiliation: Department of Urology, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kamigyo-ku, Kyoto 602-8566, Japan. fhongo@koto.kpu-m.ac.jp.
authors.forename: Fumiya
authors.initials: F
authors.lastname: Hongo
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Oishi
authors.forename: Takashi
authors.initials: T
authors.lastname: Ueda
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Naitoh
authors.forename: Terukazu
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Naya
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kamoi
authors.forename: Koji
authors.initials: K
authors.lastname: Okihara
authors.forename: Tsuneharu
authors.initials: T
authors.lastname: Miki
mesh_terms: D000328:Adult; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007668:Kidney / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011182:Postoperative Care; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib